Cargando…
Clinical relapse of immune‐mediated thrombotic thrombocytopenic purpura following COVID‐19 vaccination
De novo and relapsed immune‐mediated thrombotic thrombocytopenic purpura (iTTP) have been documented to have occurred following severe acute respiratory syndrome coronavirus 2 (COVID‐19) vaccination. Here, we present a case of a 28‐year‐old woman who received the tozinameran (BNT162b2, Pfizer‐BioNte...
Autores principales: | Deucher, William, Sukumar, Senthil, Cataland, Spero R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822264/ https://www.ncbi.nlm.nih.gov/pubmed/35155977 http://dx.doi.org/10.1002/rth2.12658 |
Ejemplares similares
-
Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management
por: Sukumar, Senthil, et al.
Publicado: (2021) -
Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020) -
SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura
por: Shah, Hridaya, et al.
Publicado: (2022) -
Novel therapies in thrombotic thrombocytopenic purpura
por: Masias, Camila, et al.
Publicado: (2017) -
Health following recovery from immune thrombotic thrombocytopenic purpura: the patient’s perspective
por: Kelley, Rachel A., et al.
Publicado: (2022)